0001551163-13-000083.txt : 20130814 0001551163-13-000083.hdr.sgml : 20130814 20130814173823 ACCESSION NUMBER: 0001551163-13-000083 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130814 DATE AS OF CHANGE: 20130814 EFFECTIVENESS DATE: 20130814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTECT PHARMACEUTICAL Corp CENTRAL INDEX KEY: 0001493526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271877179 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54001 FILM NUMBER: 131038283 BUSINESS ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 BUSINESS PHONE: 8013223401 MAIL ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 NT 10-Q 1 f12b25jun2013draft1.htm Converted by EDGARwiz



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 12b-25


NOTIFICATION OF LATE FILING

SEC File No. 000-54001  

(Check One):

CUSIP Number:  74364W 104

    Form 10-K       Form 20-F       Form 11-K     X Form 10-Q       Form 10-D       Form N-SAR        Form N-CSR


For Period Ended:   June 30, 2013

 

Transition Report on Form 10-K

 

Transition Report on Form 20-F

 

Transition Report on Form 11-K

 

Transition Report on Form 10-Q

 

Transition Report on Form  N–SAR

 

For the Transition Period Ended:_______________________________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:


PART I - REGISTRATION INFORMATION


Protect Pharmaceutical Corporation

 

Full Name of Registrant



Former Name if Applicable:


2681 East Parleys Way, Suite 204

Address of Principal Executive Office (Street and Number)


Salt Lake City, Utah 84109

City, State and Zip Code


PART II - RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)


 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 X

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form –SAR, or portion thereof, will be filed on or before the fifteenth calendar following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on the or before the fifth calendar day following the prescribed due date: and

(c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


PART III - NARRATIVE


State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N–SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The registrant has not completed its financial statements for the quarterly period ended June 30, 2013 and, accordingly, the registrant’s certifying auditors have not had the opportunity to complete their review of the financial statements to be included in the Form 10-Q.  The registrant cannot complete and file its Form 10-Q quarterly report by the due date, but is working to complete the filing by the prescribed extended due date.



PART IV - OTHER INFORMATION


(1)

Name and telephone number of person to contact in regard to this notification.


Leonard E. Neilson

      (801)    

           733-0800

 

(Name)

(Area Code)

   (Telephone Number)


(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is not, identify reports(s).

Yes  X   

 No   




(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes     

 No X  


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.



Protect Pharmaceutical Corporation

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



Date:  August 14, 2013

By  /S/ GEOFF WILLIAMS

Geoff Williams

President



INSTRUCTION:  The form may be signed by an executive officer of the registrant or by any other duly authorized representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.


ATTENTION


Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).